Related Experiment Video

Updated: May 23, 2026

Fixation and Operational Method for Abdominal Massage in T2DM Mice
05:57

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

[Which HbA1c and lipid targets in patients with type 2 diabetes?]

N Paquot1, A J Scheen

  • 1Service de Diabétologie, Nutrition et Maladies métaboliques, CHU de Liège, Belgique. nicolas.paquot@chu.ulg.ac.be

Revue Medicale De Liege
|April 10, 2012
PubMed

Insights

For type 2 diabetes patients, individualized glycemic control targets (HbA1c) balance risks and benefits. Lipid management focuses on lowering LDL cholesterol to prevent cardiovascular events.

Area of Science:

  • Endocrinology
  • Cardiology
  • Metabolic Disorders

Background:

  • Type 2 diabetes (T2D) patients face high cardiovascular risk, necessitating comprehensive management of all risk factors.
  • Previous discussions addressed blood pressure targets; this case focuses on glucose and lipid control.

Observation:

  • Glycemic control targets, measured by glycated hemoglobin (HbA1c), should be individualized based on a benefit/risk assessment.
  • Less stringent HbA1c targets are advised for patients with coronary heart disease or risk of severe hypoglycemia.
  • Stricter HbA1c targets (<7%) are recommended for patients without these risks to prevent microvascular complications.

Findings:

  • Lipid management prioritizes LDL cholesterol reduction, with targets <100 mg/dL for high-risk and <70 mg/dL for very high-risk T2D patients.
  • Dyslipidemia associated with metabolic syndrome (e.g., hypertriglyceridemia, low HDL) may be a secondary target (non-HDL cholesterol), though evidence is limited.

Implications:

  • Personalized therapeutic strategies are crucial for optimizing outcomes in T2D management.
  • Adherence to guideline-recommended lipid targets can mitigate cardiovascular risk in T2D.
  • Further research is needed to establish therapeutic targets for dyslipidemia beyond LDL cholesterol in T2D.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...